References
- Global Asthma Network (GAN). The global asthma report. 2018. cited2021 Aug 3 http://www.globalasthmareport.org
- Ebmeier S, Thayabaran D, Braithwaite I, et al. Trends in international asthma mortality: analysis of data from the WHO mortality database from 46 countries (1993-2012). Lancet. 2017;390(10098):935–5.
- Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–178.
- Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting beta-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA. 2018;319(14):1485–1496.
- Hatter L, Bruce P, Braithwaite I, Holliday, M, Fingleton, J, Weatherall, M, Beasley, R . ICS-formoterol reliever versus ICS and SABA reliever in asthma: a systematic review and meta-analysis. ERJ Open Res. 2021; 7(1):00701–2020. doi:10.1183/23120541.00701-2020 PMID: 33532465; PMCID: PMC7836558.
- Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2021. cited 2021 May 27 https://ginasthma.org/
- Nannini LJ. Asthma paradoxes: time for a new approach across the spectrum of asthma severity. Eur Respir J. 2019;53(4):1802329.
- Rodrigo GJ, Neffen H, Nannini JA, et al. Hospitalizaciones por asma aguda durante el período 1994-2004 en Argentina y Uruguay: el estudio EAGLE. Rev Am Med Resp. 2009;9:41–48.
- Nannini Jr LJ. Asthma educational program including free treatment reduced hospitalizations for asthma. Eur Respir J. 1997;10(25):101S.
- Anonymous. Using beta 2-stimulants in asthma. Drug Ther Bull. 1997;35(1):1–4.
- Choo-Kang YF, Simpson WT, Grant IW. Controlled comparison of the bronchodilator effects of three beta-adrenergic stimulant drugs administered by inhalation to patients with asthma. Br Med J. 1969;2(5652):287–289.
- Johnston SL, Edwards MR. Mechanisms of adverse effects of β-agonists in asthma. Thorax. 2009;64(9):739–741.
- Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β2-Agonist inhaler use: an observational UK study as part of the SABINA global Program. Adv Ther. 2020;37(10):4190–4208.
- Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872.
- Stanford RH, Shah MB, D’Souza AO, et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–407.
- FitzGerald JM, Tavakoli H, Lynd LD, et al. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135–140.
- Silver HS, Blanchette CM, Kamble S, et al. Relationship between short-acting β2-adrenergic agonist use and healthcare costs. Am J Manag Care. 2011;17(1):19–27.
- Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe (Sheff). 2015;11(1):14–24.
- Nannini LJ, Neumayer NS, Fernandez OM, et al. Outpatient asthma management without rescue bronchodilators? J Pulm Med Respir Res. 2019;5:024.
- Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest. 2006;130(5):1301–1311.
- Suruki RY, Daugherty JB, Boudiaf N, et al. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1):74.
- NH ASJ, Bossio JC, Calabrese CA, et al. Prevalence and features of asthma in young adults in urban areas of Argentina. Arch Bronconeumol. 2018;54(3):134–139.
- FitzGerald JM, Arnetorp S, Smare C, et al. The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK. Respir Med. 2020;171:106079.
- Price D, Wirén A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy. 2007;62(10):1189–1198.
- Ställberg B, Ekström T, Neij F, et al. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respir Med. 2008;102(10):1360–1370.
- Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. N Engl J Med. 2022 Jun 2;386(22):2071–2083. Epub 2022 May 15. PMID: 35569035